

Certificate of Biostatistics

20 August, 2021

To whom it may concern

Title of Study:

Efficacy of Omarigliptin, Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes

Chief investigator: Eiji Kawasaki

Department of Diabetes and Endocrinology,
Shin-Koga Hospital, Kurume, Fukuoka, Japan

This letter is to confirm that I have read the ethics application prepared for this study, and that in my opinion the statistical methods and techniques mentioned are appropriate for the research.

Please contact me if you have any queries.

Sincerely,

Eiji Kawasaki, M.D., Ph.D.
Diabetes Center, Shin-Koga Hospital,
120 Tenjin-cho, Kurume 830-8577, Japan.
e-kawasaki@tenjinkai.or.jp